ena-STUDY-INSTITUT PASTEUR-15-10-2021-15:32:09:393-196
Genomic characterization of Vibrio cholerae strains from Yemen 2018-2019
This study presents the genome sequences of Vibrio cholerae strains from Yemen during the 2018-2019 period and subcultured at the Institut Pasteur (Paris, France). Two main genotypes were identified among the 21 strains. Fifteen strains are serogroup O1 V. cholerae of the wave 3 of the seventh pandemic El-Tor (7PET) lineage, sublineage T13 (7PET-T13). The nine 7PET-T13 strains that were isolated in Yemen in 2019 all carry the 140-kb IncC plasmid pCNRVC190243, which contains the 20-kb pseudo-compound transposon (PCT) YemVchMDRI, providing them with resistance to macrolide, sulphonamide and cephalosporin drugs; the six 7PET-T13 strains isolated in 2018 do not carry the plasmid. The six other strains are non-O1/non-O139 V. cholerae of the sequence type (ST) 555, all isolated in Yemen in 2018. These ST555 strains all carry the 20-kb multi-drug resistance PCT YemVchMDRI, inserted in their second chromosome, also providing them with resistance to macrolide, sulphonamide and cephalosporin drugs.
This study presents the genome sequences of Vibrio cholerae strains from Yemen during the 2018-2019 period and subcultured at the Institut Pasteur (Paris, France). Two main genotypes were identified among the 21 strains. Fifteen strains are serogroup O1 V. cholerae of the wave 3 of the seventh pandemic El-Tor (7PET) lineage, sublineage T13 (7PET-T13). The nine 7PET-T13 strains that were isolated in Yemen in 2019 all carry the 140-kb IncC plasmid pCNRVC190243, which contains the 20-kb pseudo-compound transposon (PCT) YemVchMDRI, providing them with resistance to macrolide, sulphonamide and cephalosporin drugs; the six 7PET-T13 strains isolated in 2018 do not carry the plasmid. The six other strains are non-O1/non-O139 V. cholerae of the sequence type (ST) 555, all isolated in Yemen in 2018. These ST555 strains all carry the 20-kb multi-drug resistance PCT YemVchMDRI, inserted in their second chromosome, also providing them with resistance to macrolide, sulphonamide and cephalosporin drugs.